John A Heath1,2, Molly Macdonald1,2, Helen Starosta1, Samuel Hitchins3, Karen Wills4, John D Daubenton1,2. 1. Department of Paediatrics, Royal Hobart Hospital, Hobart, Tasmania, Australia. 2. Department of Medicine, University of Tasmania, Hobart, Tasmania, Australia. 3. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia. 4. Menzies Institute of Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Abstract
BACKGROUND: Tasmania is a large, relatively isolated island located south of mainland Australia with limited tertiary level paediatric oncology services. AIMS: To benchmark regional outcomes for childhood acute lymphoblastic leukaemia (ALL) against published international standards. METHODS: We undertook a retrospective cohort study, analysing the clinical characteristics and health outcomes of all children diagnosed with and treated for ALL in Tasmania, Australia between 2006 and 2015. RESULTS: Thirty-five patients aged less than 18 years were diagnosed with ALL in the study's 10-year period. Twenty-eight cases were precursor B cell in origin, with 7 cases of T-cell ALL. The great majority of children (30/35; 86%) received their entire first line treatment in Tasmania. Major treatment-related toxicities, including allergic drug reactions, and episodes of acute pancreatitis, deep venous thrombosis and bacterial sepsis, were managed locally, with one death secondary to overwhelming infection and multiorgan failure. The overall and event-free survival rates for childhood ALL were 30/35 (86%) and 28/35 (80%), respectively. CONCLUSIONS: These results compare favourably with published results from large international cooperative group trials based in developed countries. Continued local treatment with appropriate support from a dedicated specialist paediatric oncology unit is therefore justified.
BACKGROUND: Tasmania is a large, relatively isolated island located south of mainland Australia with limited tertiary level paediatric oncology services. AIMS: To benchmark regional outcomes for childhood acute lymphoblastic leukaemia (ALL) against published international standards. METHODS: We undertook a retrospective cohort study, analysing the clinical characteristics and health outcomes of all children diagnosed with and treated for ALL in Tasmania, Australia between 2006 and 2015. RESULTS: Thirty-five patients aged less than 18 years were diagnosed with ALL in the study's 10-year period. Twenty-eight cases were precursor B cell in origin, with 7 cases of T-cell ALL. The great majority of children (30/35; 86%) received their entire first line treatment in Tasmania. Major treatment-related toxicities, including allergic drug reactions, and episodes of acute pancreatitis, deep venous thrombosis and bacterial sepsis, were managed locally, with one death secondary to overwhelming infection and multiorgan failure. The overall and event-free survival rates for childhood ALL were 30/35 (86%) and 28/35 (80%), respectively. CONCLUSIONS: These results compare favourably with published results from large international cooperative group trials based in developed countries. Continued local treatment with appropriate support from a dedicated specialist paediatric oncology unit is therefore justified.
Authors: Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Martin Schrappe; Stephen P Hunger; Ching-Hon Pui; Vaskar Saha; Paul S Gaynon; André Baruchel; Valentino Conter; Jacques Otten; Akira Ohara; Anne Birgitta Versluys; Gabriele Escherich; Mats Heyman; Lewis B Silverman; Keizo Horibe; Georg Mann; Bruce M Camitta; Jochen Harbott; Hansjörg Riehm; Sue Richards; Meenakshi Devidas; Martin Zimmermann Journal: N Engl J Med Date: 2012-04-12 Impact factor: 91.245
Authors: Trudy D Buitenkamp; Shai Izraeli; Martin Zimmermann; Erik Forestier; Nyla A Heerema; Marry M van den Heuvel-Eibrink; Rob Pieters; Carin M Korbijn; Lewis B Silverman; Kjeld Schmiegelow; Der-Cheng Liang; Keizo Horibe; Maurizio Arico; Andrea Biondi; Giuseppe Basso; Karin R Rabin; Martin Schrappe; Gunnar Cario; Georg Mann; Maria Morak; Renate Panzer-Grümayer; Veerle Mondelaers; Tim Lammens; Hélène Cavé; Batia Stark; Ithamar Ganmore; Anthony V Moorman; Ajay Vora; Stephen P Hunger; Ching-Hon Pui; Charles G Mullighan; Atsushi Manabe; Gabriele Escherich; Jerzy R Kowalczyk; James A Whitlock; C Michel Zwaan Journal: Blood Date: 2013-11-12 Impact factor: 22.113